Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28710888 | 0.76 | MEN1 (0.50) | MEN1KMT2ALMNANPSR1CYP3A4 | |
| SCHEMBL3341865 | 0.74 | MEN1 (0.48) | MEN1KMT2ALMNANPSR1CYP3A4 | |
| SCHEMBL6005836 | 0.70 | CYP3A4 (0.48) | MEN1KMT2ALMNANPSR1CYP3A4 | |
| SCHEMBL11941449 | 0.70 | MEN1 (0.46) | MEN1KMT2ALMNANPSR1CYP3A4 | |
| SCHEMBL11941497 | 0.70 | MEN1 (0.46) | MEN1KMT2ALMNANPSR1CYP3A4 | |
| SCHEMBL10690351 | 0.70 | KMT2A (0.46) | MEN1KMT2ALMNANPSR1 | |
| SCHEMBL15344682 | 0.69 | CYP3A4 (0.33) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL28857096 | 0.68 | MEN1 (0.48) | MEN1KMT2ALMNANPSR1CYP3A4 | |
| SCHEMBL6736653 | 0.66 | MEN1 (0.41) | MEN1KMT2ALMNANPSR1CYP3A4 | |
| SCHEMBL14205235 | 0.65 | NPSR1 (0.33) | MEN1KMT2ALMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783511-B2 | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease | LYCERA CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160311787-A1 | CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | MERCK SHARP & DOHME LLC | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311787-A1 | CARBAMATE BENZOXAZINE PROPIONIC ACIDS AND ACID DERIVATIVES FOR MODULATION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE | RORA, RORB, RORC | MEN1 2347/4885KMT2A 780/4885LMNA 3946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.